Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Income (2016 - 2025)

Lineage Cell Therapeutics' Operating Income history spans 16 years, with the latest figure at -$6.5 million for Q4 2025.

  • For Q4 2025, Operating Income fell 28.14% year-over-year to -$6.5 million; the TTM value through Dec 2025 reached -$36.6 million, down 70.5%, while the annual FY2025 figure was -$36.6 million, 70.5% down from the prior year.
  • Operating Income reached -$6.5 million in Q4 2025 per LCTX's latest filing, down from -$3.8 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$3.8 million in Q3 2025 to a low of -$28.2 million in Q4 2021.
  • Average Operating Income over 5 years is -$7.7 million, with a median of -$6.5 million recorded in 2025.
  • Peak YoY movement for Operating Income: tumbled 380.07% in 2021, then soared 76.49% in 2022.
  • A 5-year view of Operating Income shows it stood at -$28.2 million in 2021, then skyrocketed by 76.49% to -$6.6 million in 2022, then grew by 4.17% to -$6.4 million in 2023, then increased by 19.68% to -$5.1 million in 2024, then fell by 28.14% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Operating Income are -$6.5 million (Q4 2025), -$3.8 million (Q3 2025), and -$19.8 million (Q2 2025).